Product Description
Bexmarilimab is being developed by Faron for the treatment of patients with Localised Renal Cell and Colon Carcinoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05104905?term=Bexmarilimab&draw=2&rank=1)
Mechanisms of Action: CLEVER1 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Orphan Drug - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Faron
Company Location: Europe
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Finland, Spain, United Kingdom, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07460986 |
BEXAR | P2 |
Not yet recruiting |
Sarcoma |
2028-07-01 |
12% |
2026-03-11 |
Primary Endpoints|Treatments |
NCT05428969 |
BEXMAB | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia |
2027-03-01 |
12% |
2026-04-24 |
|
2025-525144-18-00 |
MEDOPP0799 | P2 |
Not yet recruiting |
Sarcoma |
2029-07-01 |
|||
2024-517444-64-00 |
FP2CLI004 | P2 |
Recruiting |
Myelodysplastic Syndrome|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia |
2025-06-01 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/01/2025 |
News Article |
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting |
|
12/10/2024 |
News Article |
Faron presents BEXMAB data at ASH Annual Meeting |
|
11/20/2024 |
News Article |
The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment |
|
05/16/2024 |
News Article |
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 |